SCPH Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -155.1% compared to scPharmaceuticals's net margin of -49.65%. scPharmaceuticals's return on equity of -370.01% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 492.45%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.4%. Given that scPharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe scPharmaceuticals is more attractive than NovaBay Pharmaceuticals.

scPharmaceuticals has a beta of 0.380, which suggesting that the stock is 61.958% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

scPharmaceuticals quarterly revenues are $12.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. scPharmaceuticals's net income of -$18.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 3.14x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -155.1% compared to scPharmaceuticals's net margin of --. scPharmaceuticals's return on equity of -370.01% beat Palatin Technologies's return on equity of --.

scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 492.45%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 2930.3%. Given that Palatin Technologies has higher upside potential than scPharmaceuticals, analysts believe Palatin Technologies is more attractive than scPharmaceuticals.

scPharmaceuticals has a beta of 0.380, which suggesting that the stock is 61.958% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

scPharmaceuticals quarterly revenues are $12.2M, which are larger than Palatin Technologies quarterly revenues of --. scPharmaceuticals's net income of -$18.8M is higher than Palatin Technologies's net income of --. Notably, scPharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 3.14x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -155.1% compared to scPharmaceuticals's net margin of -241.28%. scPharmaceuticals's return on equity of -370.01% beat Regenxbio's return on equity of -70.45%.

scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 492.45%. On the other hand Regenxbio has an analysts' consensus of $32.50 which suggests that it could grow by 387.26%. Given that scPharmaceuticals has higher upside potential than Regenxbio, analysts believe scPharmaceuticals is more attractive than Regenxbio.

scPharmaceuticals has a beta of 0.380, which suggesting that the stock is 61.958% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.294%.

scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

scPharmaceuticals quarterly revenues are $12.2M, which are smaller than Regenxbio quarterly revenues of $21.2M. scPharmaceuticals's net income of -$18.8M is higher than Regenxbio's net income of -$51.2M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 3.14x versus 3.96x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -155.1% compared to scPharmaceuticals's net margin of --. scPharmaceuticals's return on equity of -370.01% beat Theriva Biologics's return on equity of --.

scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 492.45%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 358.02%. Given that scPharmaceuticals has higher upside potential than Theriva Biologics, analysts believe scPharmaceuticals is more attractive than Theriva Biologics.

scPharmaceuticals has a beta of 0.380, which suggesting that the stock is 61.958% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

scPharmaceuticals quarterly revenues are $12.2M, which are larger than Theriva Biologics quarterly revenues of --. scPharmaceuticals's net income of -$18.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 3.14x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.